NRx Pharmaceuticals stock rating reiterated at Buy by BTIG on FDA progress

TL;DR

Reports differ across sources; according to finance.yahoo.com, - 5 Biotech stocks tapping into unmet mental health treatment needs NRx Pharmaceuticals (NASDAQ:NRXP) executives used the company’s fourth-quarter 2025 results call to outline what they described as a “pivotal and transformative” year, highlighting advancing regulatory pathways for preservative-free ketamine and an investigational ketamine product, as well as an expanded strategy for its NRX-101 program tied to transcranial magnetic stimulation (TMS).